SlideShare una empresa de Scribd logo
1 de 29
Centralization of Esophageal Cancer Treatment Peter D. Siersema Dept. of Gastroenterology and Hepatology
Factors affecting outcome of esophageal cancer treatment ,[object Object]
Factors affecting outcome of esophageal cancer treatment ,[object Object],[object Object],[object Object],[object Object],[object Object]
Factors affecting outcome of esophageal cancer treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Outcome of esophagectomy Practice makes perfect …..
Hospital volume and esophagectomy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],van Lanschot et al. Cancer 2001; 91: 1574-8
[object Object],Hospital volume and esophagectomy van Lanschot et al. Cancer 2001; 91: 1574-8
[object Object],Hospital volume and esophagectomy van Lanschot et al. Cancer 2001; 91: 1574-8
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Surgeon volume and esophagectomy Birkmeyer et al. NEJM 2003; 349: 2117-27
[object Object],Surgeon volume and esophagectomy Birkmeyer et al. NEJM 2003; 349: 2117-27
[object Object],Surgeon volume and esophagectomy Birkmeyer et al. NEJM 2003; 349: 2117-27
Dutch guidelines on esophageal cancer (2005)
Dutch guidelines on esophageal cancer (2005) “ At least 10 times per year” “ Inspection of Healthcare” “ Quality of esophageal cancer resection requires experience”
High-volume vs. Low-volume Literature  Gruen et al. CA Cancer J Clin 2009; 59: 192-211 1 1 2 1 6 28 Studies Short- term Long-term Short- term Long-term Short-/Long-term 1 0 Hospital volume Quality of life 0 1 Hospital specialization 1 1 Hospital volume Survival 0 6 0 16 2 1 Surgeon volume 0 2 Surgeon volume 9 4 Hospital volume In-hospital mortality Results S  NS Level Outcome
High-volume vs. Low-volume Literature  Gruen et al. CA Cancer J Clin 2009; 59: 192-211 1 1 2 1 6 28 Studies Short- term Long-term Short- term Long-term Short-/Long-term 1 0 Hospital volume Quality of life 0 1 Hospital specialization 1 1 Hospital volume Survival 0 6 0 16 2 1 Surgeon volume 0 2 Surgeon volume 9 4 Hospital volume In-hospital mortality Results S  NS Level Outcome
High-volume vs. Low-volume Literature  Gruen et al. CA Cancer J Clin 2009; 59: 192-211
High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211
High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211
[object Object],[object Object],[object Object],High-volume vs. Low-volume Literature  Gruen et al. CA Cancer J Clin 2009; 59: 192-211
Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004
Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004 Volume?
Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004 Outcome?
Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004 Outcome?
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],How to Use Outcome Analysis Quality improvement in a Dutch Region Wouters et al. Surg Oncol 2009; 16: 1789-98
Concentration of Esophagectomy Results: Treatment Outcome Wouters et al. Surg Oncol 2009; 16: 1789-98
Concentration of Esophagectomy Results: 2-years survival Log-rank   P =0.03 52%  (2000-2005) 43%  (1995-1999) 38%  (1990-1994) Log rank: p2 vs p3:  p =0.01  p1 vs p3:  p <0.001  p1 vs p2:  p =0.34 p3 p2 p2 p1 Wouters et al. Surg Oncol 2009; 16: 1789-98
[object Object],[object Object],[object Object],[object Object],[object Object],Outcome of esophagectomy Centralization or regionalization?
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Outcome of esophagectomy Centralization or regionalization?
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Outcome of esophagectomy Centralization or regionalization?

Más contenido relacionado

La actualidad más candente

Liver transplantation for cancer
Liver transplantation for cancerLiver transplantation for cancer
Liver transplantation for cancerGian Luca Grazi
 
Low Radiation Dose effect of Tomotherapy for Hepatocellular Carcinoma
Low Radiation Dose effect of Tomotherapy for Hepatocellular CarcinomaLow Radiation Dose effect of Tomotherapy for Hepatocellular Carcinoma
Low Radiation Dose effect of Tomotherapy for Hepatocellular Carcinomaaccurayexchange
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMKanhu Charan
 
CRC_PNR & EMVI_prognosis_BJCpaper
CRC_PNR & EMVI_prognosis_BJCpaperCRC_PNR & EMVI_prognosis_BJCpaper
CRC_PNR & EMVI_prognosis_BJCpaperLeslie Samuel
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationAshutosh Mukherji
 
cours chimioembolisation CHC dec 2014
cours chimioembolisation CHC dec 2014cours chimioembolisation CHC dec 2014
cours chimioembolisation CHC dec 2014Dr Sameh AWAD
 
2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...
2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...
2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...drewzer
 
radiotherapy-pancreatic cancer
radiotherapy-pancreatic cancerradiotherapy-pancreatic cancer
radiotherapy-pancreatic cancerfondas vakalis
 
Bladder cancer treatment
Bladder cancer treatmentBladder cancer treatment
Bladder cancer treatmentGil Lederman
 
Treatment Of Stage Iii Nsclc The Role Of Radiation Therapy
Treatment Of Stage Iii Nsclc  The Role Of Radiation TherapyTreatment Of Stage Iii Nsclc  The Role Of Radiation Therapy
Treatment Of Stage Iii Nsclc The Role Of Radiation Therapyfondas vakalis
 
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...Diaa A. Hameed
 
Durham ir approaches
Durham ir approachesDurham ir approaches
Durham ir approachesIsha Rabani
 
Long Term Survival RF Ablation for Primary and Metastatic Liver Tumors
Long Term Survival RF Ablation for Primary and Metastatic Liver TumorsLong Term Survival RF Ablation for Primary and Metastatic Liver Tumors
Long Term Survival RF Ablation for Primary and Metastatic Liver TumorsISWANTO SUCANDY, M.D, F.A.C.S
 
Balanced Approach To Esophageal Cancer
Balanced Approach To Esophageal CancerBalanced Approach To Esophageal Cancer
Balanced Approach To Esophageal Cancerfondas vakalis
 
Primary Surgery vs Chemoradiotherapy for Oropahryngeal Cancer
Primary Surgery vs Chemoradiotherapy for Oropahryngeal CancerPrimary Surgery vs Chemoradiotherapy for Oropahryngeal Cancer
Primary Surgery vs Chemoradiotherapy for Oropahryngeal CancerGloria Ate
 
Chemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dashChemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dashPrasanta Dash
 
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...Clinical outcome, proteome kinetics and angiogenic factors in serum after the...
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...Enrique Moreno Gonzalez
 

La actualidad más candente (20)

Liver transplantation for cancer
Liver transplantation for cancerLiver transplantation for cancer
Liver transplantation for cancer
 
Stomach adjuvant rt
Stomach adjuvant rtStomach adjuvant rt
Stomach adjuvant rt
 
20150100.0 00015
20150100.0 0001520150100.0 00015
20150100.0 00015
 
Low Radiation Dose effect of Tomotherapy for Hepatocellular Carcinoma
Low Radiation Dose effect of Tomotherapy for Hepatocellular CarcinomaLow Radiation Dose effect of Tomotherapy for Hepatocellular Carcinoma
Low Radiation Dose effect of Tomotherapy for Hepatocellular Carcinoma
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
 
CRC_PNR & EMVI_prognosis_BJCpaper
CRC_PNR & EMVI_prognosis_BJCpaperCRC_PNR & EMVI_prognosis_BJCpaper
CRC_PNR & EMVI_prognosis_BJCpaper
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: Chemoradiation
 
cours chimioembolisation CHC dec 2014
cours chimioembolisation CHC dec 2014cours chimioembolisation CHC dec 2014
cours chimioembolisation CHC dec 2014
 
2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...
2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...
2015 International Association for the Study of Lung Cancer (IASLC) Annual Co...
 
radiotherapy-pancreatic cancer
radiotherapy-pancreatic cancerradiotherapy-pancreatic cancer
radiotherapy-pancreatic cancer
 
Bladder cancer treatment
Bladder cancer treatmentBladder cancer treatment
Bladder cancer treatment
 
Treatment Of Stage Iii Nsclc The Role Of Radiation Therapy
Treatment Of Stage Iii Nsclc  The Role Of Radiation TherapyTreatment Of Stage Iii Nsclc  The Role Of Radiation Therapy
Treatment Of Stage Iii Nsclc The Role Of Radiation Therapy
 
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...
 
Durham ir approaches
Durham ir approachesDurham ir approaches
Durham ir approaches
 
Research Discussion
Research DiscussionResearch Discussion
Research Discussion
 
Long Term Survival RF Ablation for Primary and Metastatic Liver Tumors
Long Term Survival RF Ablation for Primary and Metastatic Liver TumorsLong Term Survival RF Ablation for Primary and Metastatic Liver Tumors
Long Term Survival RF Ablation for Primary and Metastatic Liver Tumors
 
Balanced Approach To Esophageal Cancer
Balanced Approach To Esophageal CancerBalanced Approach To Esophageal Cancer
Balanced Approach To Esophageal Cancer
 
Primary Surgery vs Chemoradiotherapy for Oropahryngeal Cancer
Primary Surgery vs Chemoradiotherapy for Oropahryngeal CancerPrimary Surgery vs Chemoradiotherapy for Oropahryngeal Cancer
Primary Surgery vs Chemoradiotherapy for Oropahryngeal Cancer
 
Chemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dashChemotherapy in ca urinary bladder dr prasanta dash
Chemotherapy in ca urinary bladder dr prasanta dash
 
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...Clinical outcome, proteome kinetics and angiogenic factors in serum after the...
Clinical outcome, proteome kinetics and angiogenic factors in serum after the...
 

Destacado

Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...European School of Oncology
 
Esophageal cancer
Esophageal cancerEsophageal cancer
Esophageal cancerAhmed Allam
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
ASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI CancersASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI CancersOSUCCC - James
 
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 

Destacado (6)

Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
 
Esophageal cancer
Esophageal cancerEsophageal cancer
Esophageal cancer
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
ASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI CancersASCO Review 2016 Upper GI Cancers
ASCO Review 2016 Upper GI Cancers
 
11 esophageal cancer
11 esophageal cancer11 esophageal cancer
11 esophageal cancer
 
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 

Similar a Factors Affecting Esophageal Cancer Treatment Outcomes

Current evidence for laparoscopic surgery in colorectal cancers
Current evidence for laparoscopic surgery in colorectal cancersCurrent evidence for laparoscopic surgery in colorectal cancers
Current evidence for laparoscopic surgery in colorectal cancersApollo Hospitals
 
BALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABC
BALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABCBALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABC
BALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABCEuropean School of Oncology
 
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology
 
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology
 
Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...
Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...
Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...European School of Oncology
 
Lap vs Open Colorectal Resection
Lap vs Open Colorectal ResectionLap vs Open Colorectal Resection
Lap vs Open Colorectal ResectionDhaval Mangukiya
 
DU PERF AND ABX
DU PERF AND ABX DU PERF AND ABX
DU PERF AND ABX NHS
 
Presentation study protocol
Presentation study protocolPresentation study protocol
Presentation study protocolSteven Lips
 
recent advances in hepatobiliary and GI surgery
recent advances in hepatobiliary and GI surgeryrecent advances in hepatobiliary and GI surgery
recent advances in hepatobiliary and GI surgeryhr77
 
O. Glehen - HIPEC Colorectal and Gastric
O. Glehen - HIPEC Colorectal and GastricO. Glehen - HIPEC Colorectal and Gastric
O. Glehen - HIPEC Colorectal and GastricGlehen
 
Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?King Hussien Cancer Center
 
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONSMANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONSMohamed Abdulla
 
Evidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric CancerEvidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric CancerPradeep Dhanasekaran
 
Chemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxChemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxAtulGupta369
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancerDr Rushi Panchal
 
Gastric cancer management
Gastric cancer managementGastric cancer management
Gastric cancer managementNabeel Yahiya
 

Similar a Factors Affecting Esophageal Cancer Treatment Outcomes (20)

Current evidence for laparoscopic surgery in colorectal cancers
Current evidence for laparoscopic surgery in colorectal cancersCurrent evidence for laparoscopic surgery in colorectal cancers
Current evidence for laparoscopic surgery in colorectal cancers
 
Ca esophagus trails
Ca esophagus trailsCa esophagus trails
Ca esophagus trails
 
BALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABC
BALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABCBALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABC
BALKAN MCO 2011 - E. Vrdoljak - Locoregional therapy in LABC
 
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
 
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
 
Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...
Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...
Endoscopy in Gastrointestinal Oncology - Slide 15 - D. Fisher - Colorectal ca...
 
Lap vs Open Colorectal Resection
Lap vs Open Colorectal ResectionLap vs Open Colorectal Resection
Lap vs Open Colorectal Resection
 
Imrt For Anal Cancer
Imrt For Anal CancerImrt For Anal Cancer
Imrt For Anal Cancer
 
DU PERF AND ABX
DU PERF AND ABX DU PERF AND ABX
DU PERF AND ABX
 
Lung
LungLung
Lung
 
Presentation study protocol
Presentation study protocolPresentation study protocol
Presentation study protocol
 
recent advances in hepatobiliary and GI surgery
recent advances in hepatobiliary and GI surgeryrecent advances in hepatobiliary and GI surgery
recent advances in hepatobiliary and GI surgery
 
O. Glehen - HIPEC Colorectal and Gastric
O. Glehen - HIPEC Colorectal and GastricO. Glehen - HIPEC Colorectal and Gastric
O. Glehen - HIPEC Colorectal and Gastric
 
Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?
 
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONSMANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
MANAGEMENTOF METASTATIC OR ADVANCED GASTRIC CANCER : FIRST LINE OPTIONS
 
Oesophageal cancer osama
Oesophageal cancer osamaOesophageal cancer osama
Oesophageal cancer osama
 
Evidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric CancerEvidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric Cancer
 
Chemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptxChemoradiotherapy Anal canal cancer.pptx
Chemoradiotherapy Anal canal cancer.pptx
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancer
 
Gastric cancer management
Gastric cancer managementGastric cancer management
Gastric cancer management
 

Más de European School of Oncology

A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 
J.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the artJ.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the artEuropean School of Oncology
 
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)European School of Oncology
 

Más de European School of Oncology (20)

A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 
J.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the artJ.B. Vermorken - Head and neck - State of the art
J.B. Vermorken - Head and neck - State of the art
 
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
 

Factors Affecting Esophageal Cancer Treatment Outcomes

  • 1. Centralization of Esophageal Cancer Treatment Peter D. Siersema Dept. of Gastroenterology and Hepatology
  • 2.
  • 3.
  • 4.
  • 5. Outcome of esophagectomy Practice makes perfect …..
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12. Dutch guidelines on esophageal cancer (2005)
  • 13. Dutch guidelines on esophageal cancer (2005) “ At least 10 times per year” “ Inspection of Healthcare” “ Quality of esophageal cancer resection requires experience”
  • 14. High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211 1 1 2 1 6 28 Studies Short- term Long-term Short- term Long-term Short-/Long-term 1 0 Hospital volume Quality of life 0 1 Hospital specialization 1 1 Hospital volume Survival 0 6 0 16 2 1 Surgeon volume 0 2 Surgeon volume 9 4 Hospital volume In-hospital mortality Results S NS Level Outcome
  • 15. High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211 1 1 2 1 6 28 Studies Short- term Long-term Short- term Long-term Short-/Long-term 1 0 Hospital volume Quality of life 0 1 Hospital specialization 1 1 Hospital volume Survival 0 6 0 16 2 1 Surgeon volume 0 2 Surgeon volume 9 4 Hospital volume In-hospital mortality Results S NS Level Outcome
  • 16. High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211
  • 17. High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211
  • 18. High-volume vs. Low-volume Literature Gruen et al. CA Cancer J Clin 2009; 59: 192-211
  • 19.
  • 20. Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004
  • 21. Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004 Volume?
  • 22. Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004 Outcome?
  • 23. Volume or Outcome? Esophagectomies in NL Data-source: PRISMANT 1990-2004 Outcome?
  • 24.
  • 25. Concentration of Esophagectomy Results: Treatment Outcome Wouters et al. Surg Oncol 2009; 16: 1789-98
  • 26. Concentration of Esophagectomy Results: 2-years survival Log-rank P =0.03 52% (2000-2005) 43% (1995-1999) 38% (1990-1994) Log rank: p2 vs p3: p =0.01 p1 vs p3: p <0.001 p1 vs p2: p =0.34 p3 p2 p2 p1 Wouters et al. Surg Oncol 2009; 16: 1789-98
  • 27.
  • 28.
  • 29.

Notas del editor

  1. One of the procedures showing a strong volume-outcome relationship are esophageal resections for cancer.
  2. One of the procedures showing a strong volume-outcome relationship are esophageal resections for cancer.
  3. One of the procedures showing a strong volume-outcome relationship are esophageal resections for cancer.
  4. One of the procedures showing a strong volume-outcome relationship are esophageal resections for cancer.
  5. One of the procedures showing a strong volume-outcome relationship are esophageal resections for cancer.
  6. An example in regard to the last point: Esophageal resections for cancer, are high-risk surgical procedures for which strong variation in outcome is demonstrated between low and high volume hospitals....also in our country. In this funnel-plot based on data from the National In-Patient Registry (PRISMANT), we see all hospitals performing esophageal resections in a 15 years period, presented as small dots. On the lower right, there are 2 or 3 high-volume centers, performing more than 20 resections a year with a mortality rate of approximately 5%. To the left the other 90 hospitals are in a big low-volume cloud, with an enormous variation in mortality (in some hospitals more than 1 in 4 patients died post operatively).
  7. An example in regard to the last point: Esophageal resections for cancer, are high-risk surgical procedures for which strong variation in outcome is demonstrated between low and high volume hospitals....also in our country. In this funnel-plot based on data from the National In-Patient Registry (PRISMANT), we see all hospitals performing esophageal resections in a 15 years period, presented as small dots. On the lower right, there are 2 or 3 high-volume centers, performing more than 20 resections a year with a mortality rate of approximately 5%. To the left the other 90 hospitals are in a big low-volume cloud, with an enormous variation in mortality (in some hospitals more than 1 in 4 patients died post operatively).
  8. An example in regard to the last point: Esophageal resections for cancer, are high-risk surgical procedures for which strong variation in outcome is demonstrated between low and high volume hospitals....also in our country. In this funnel-plot based on data from the National In-Patient Registry (PRISMANT), we see all hospitals performing esophageal resections in a 15 years period, presented as small dots. On the lower right, there are 2 or 3 high-volume centers, performing more than 20 resections a year with a mortality rate of approximately 5%. To the left the other 90 hospitals are in a big low-volume cloud, with an enormous variation in mortality (in some hospitals more than 1 in 4 patients died post operatively).
  9. An example in regard to the last point: Esophageal resections for cancer, are high-risk surgical procedures for which strong variation in outcome is demonstrated between low and high volume hospitals....also in our country. In this funnel-plot based on data from the National In-Patient Registry (PRISMANT), we see all hospitals performing esophageal resections in a 15 years period, presented as small dots. On the lower right, there are 2 or 3 high-volume centers, performing more than 20 resections a year with a mortality rate of approximately 5%. To the left the other 90 hospitals are in a big low-volume cloud, with an enormous variation in mortality (in some hospitals more than 1 in 4 patients died post operatively).
  10. Probably most of you have heard about the centralization project in the region of the Comprehensive Cancer Center Leiden... In 2000 none of the 11 hospitals performed more than 7 esophagectomies a year. Because of the growing evidence for a volume-outcome relation for esophageal cancer surgery in the literature,... the surgical oncologists decided to audit the quality of care in the region. 10 years retrospective data were retrieved from all hospitals .........and remarkable differences in outcome were revealed. This led to the concentration of procedures in 3 hospitals, based on their observed outcome. The audit was continued to monitor the effects of this outcome-based centralization from the year 2000 untill now. Not only for esophageal resections..., but also pancreatic, liver and soft tissue resections.
  11. In this table we see the updated outcome data....There was a dramtic fall in hospital mortality from 12% in the 1995-1999 period to 4% in the 2000-2004 period. This was accompanied with a significant reduction in hospital stay and tumor-free margins.
  12. Also, a significant improvement in survival was observed in the last 5-years episode ( marked with p3 ...for period three...in this figure).